Healthcare: Is Zolgensma's $2.1 Million Price Tag Ridiculous?

<div>Here's why paying $2 million for Novartis' revolutionary gene therapy for SMA may not be as crazy as it sounds. </div> <div>Also, why shares slumped after BioMarin reported its gene therapy may virtually eliminate bleeding in hemophilia A patients.</div> <p><strong>Check out more of our content here:</strong></p> <ul> <li><a href= "https://www.fool.com/podcasts/?utm_source=podcasts&utm_medium=podcasts&utm_campaign=industryfocus" target="_blank" rel="noopener">TMF's podcast portal</a></li> <li><a href="https://www.youtube.com/user/TheMotleyFool" target= "_blank" rel="noopener">YouTube</a></li> <li><a href="https://twitter.com/mfindustryfocus?lang=en" target= "_blank" rel="noopener">Twitter</a></li> <li><a href="https://m.facebook.com/groups/217114601988296">Join Our Motley Fool Podcast Facebook Group</a></li> <li><a href= "https://www.linkedin.com/company/the-motley-fool">LinkedIn</a></li> <li><a href= "https://www.fool.com/ecap/the_motley_fool/stock-up/?aid=9205&source=isusitsz0000002&ftm_cam=stockup&ftm_veh=sidebarhelp&ftm_mes=signup"> StockUp, The Motley Fool's weekly email newsletter</a></li> </ul>